Three histologically distinct cancers of the uterine corpus: A case report and review of the literature

HISASHI MASUYAMA¹, JUNKO HARAGA¹, TAKASHI NISHIDA¹, CHIKAKO OGAWA¹, TOMOYUKI KUSUMOTO¹, KEIICHIRO NAKAMURA¹, NORIKO SEKI¹, HIROYUKI YANAI² and YUJI HIRAMATSU¹

¹Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences; ²Department of Pathology, Okayama University Hospital, Okayama 700-8558, Japan

Received October 2, 2015; Accepted January 29, 2016

DOI: 10.3892/mco.2016.770

Abstract. Collision tumors, which are characterized by the coexistence of two or more completely distinct and independent tumors in the uterine corpus, are very rare. A collision tumor is mainly composed of two distinct tumor types, epithelial and mesenchymal. To the best of our knowledge, there has only been a single case in which a choriocarcinoma with an endometrial carcinoma were coexistent but histologically distinct. We herein report the first case of a collision tumor in a 52-year-old woman, with a history of two pregnancies and two deliveries. The collision tumor was composed of three histologically distinct neoplasms in the uterine corpus, namely an endometrioid carcinoma, an undifferentiated carcinoma and a choriocarcinoma. The patient underwent hysterectomy, bilateral adnexectomy and pelvic lymph node dissection, followed by six cycles of adjuvant chemotherapy with paclitaxel/carboplatin due to the high risk of endometrial cancer, and an additional five cycles of chemotherapy with methotrexate as the β-human chorionic gonadotropin level was beyond the normal range. Following adjuvant chemotherapy, the tumor markers were within normal limits and no relapses of the cancer have been observed during 1 year of follow-up. Diagnosing a collision tumor prior to surgery is difficult if the neoplasms are in close proximity, or if one of the tumors predominates. Careful pathological examination is crucial for accurately diagnosing the neoplasms in a collision tumor and ensuring appropriate management and a favorable prognosis.

Introduction

Tumors that occur in the uterine corpus include epithelial, mesenchymal, mixed epithelial and mesenchymal, miscellaneous, lymphoid and myeloid and secondary tumors, as well as trophoblastic disease (1). Endometrial cancer is the third most common cause of death among gynecological cancers, following ovarian and cervical cancer, with increasing incidence rates in several countries (2). This may be attributed to the increasing number of elderly individuals and increasing rates of obesity (2). Endometrial cancer includes several carcinomas, which are divided into type I and II cancers and include endometrioid adenocarcinomas, mucinous adenocarcinomas, serous carcinomas, clear-cell carcinomas and several other rare forms, such as neuroendocrine tumors, including small-cell, mixed, undifferentiated and dedifferentiated carcinomas (3).

In addition, choriocarcinoma is a malignant trophoblastic tumor, usually of the placenta, that may also occur in the uterine corpus. Choriocarcinoma belongs to the malignant end of the spectrum of gestational trophoblastic disease, with 20% of this disease occurring after normal pregnancy (4). However, it is rare for trophoblastic disease to present in the uterus of postmenopausal women (5). Furthermore, non-gestational choriocarcinomas occur in the absence of a preceding gestation, and often tend to occur as a component of an ovarian germ cell tumor (6). Almost all primary non-gestational choriocarcinomas of the female genital tract have been described in the ovaries (7,8).

The number of reports in the literature regarding endometrial cancer in which choriocarcinoma differentiation occurs in the uterine corpus is limited (9), with only a single report of coexistence of a mixed adenocarcinoma and a choriocarcinoma (10). We herein report the first case of a collision tumor in the uterine corpus composed of three histologically distinct cancers, namely an endometrioid carcinoma, an undifferentiated carcinoma and a choriocarcinoma.

Case report

Our patient was a 52-year-old woman with a history of two pregnancies and two deliveries; the last delivery was when she...
was 28 years old. The patient was 156 cm in height, weighed 51 kg, and had a body mass index of 20.95 kg/m². The history of menstrual cycles was regular and she had gone through menopause at the age of 51 years. The surgical history included an appendectomy at the age of 19 years, but there was no family history of cancer. The patient consulted a gynecologist with a main complaint of moderate genital bleeding. A 35x30-mm mass lesion, which bled easily, was detected in the cervix.

The patient was referred to our hospital and, after undergoing a detailed examination, received further treatment due to the suspicion of cervical cancer. During the first visit to our hospital, a pelvic examination revealed an enlarged cervix, while the digital examination revealed extension to the parametrium on either side of the uterus. The colposcopic examination revealed that the invasive carcinoma was a large polypoid mass in the cervical canal. The cytological diagnosis of the cervical lesion was a high-grade squamous intraepithelial lesion and the pathological diagnosis, using a punch biopsy, indicated a squamous cell carcinoma (SCC). Transvaginal ultrasonography revealed a mixed echogenic mass in the cervix, sized 49x49x57 mm (Fig. 1A). Magnetic resonance imaging (MRI) revealed a hyperintense cervical mass sized 55x51x52 mm, invading the lower uterine segment (Fig. 1B). Positron emission tomography-computed tomography (CT) revealed intense fludeoxyglucose activity correlating with a cervical and endometrial mass, without signs of metastasis to other organs or to the pelvic and paraaortic lymph nodes (Fig. 1C). The tumor marker carbohydrate antigen (CA)-125 was elevated (91.8 U/ml), but other markers, including carcinoembryonic antigen, CA19-9 and SCC antigen, were within the normal range.

With an initial diagnosis of stage IB2 cervical cancer, the patient underwent radical hysterectomy, bilateral adnexectomy and pelvic lymph node dissection. The abdominal cavity was free of ascites, disseminated lesions and adhesions to adjacent organs. Three distinct tumors were identified in the resected specimen, one in the lower segment, one in the middle segment and one in the fundus of the uterine corpus (Fig. 2A). The histopathological examination of the masses revealed that they were three histologically distinct cancers: An undifferentiated carcinoma of the lower segment, invading half the thickness of the myometrium (Fig. 2B); an endometrioid adenocarcinoma with squamous differentiation, grade 2, confined to the endometrium in the middle segment (Fig. 2C); and a choriocarcinoma with lymphovascular space invasion, but without an endometrioid adenocarcinoma component, in the fundus of the uterine corpus (Fig. 2D), metastasizing to the lymph nodes of the left external iliac artery. There was no communication between the three lesions in the uterine corpus.

The clinical diagnosis was stage IIIIC1 endometrial cancer [International Federation of Gynecology and Obstetrics 2008 (1)] and choriocarcinoma. The patient was diagnosed with three histologically distinct neoplasms in the uterine corpus. After the operation, chemotherapy with paclitaxel 175 mg/m² plus carboplatin area under the curve = 6 (TC regimen) was administered, due to the high risk of endometrial cancer. Six treatment cycles were completed without dose reduction or suspension of treatment. The β-human chorionic gonadotropin (hCG) level was 19.5 mIU/ml when the pathological results of the coexistence with a choriocarcinoma were obtained, and the β-hCG level (1.0 mIU/ml) after six cycles of TC was above the normal range (0-0.5 mIU/ml), although other tumor markers were within normal limits, and CT revealed no cancer recurrence or metastasis. Five additional cycles using methotrexate (20 mg/m² body surface x 5 days) were administered and completed without dose reduction or suspension of treatment. After the five cycles, the tumor markers, including the β-hCG level, were within normal limits, without cancer relapse during 1 year of follow-up.

**Discussion**

We reported a case with three histologically distinct cancers in the uterine corpus: An endometrioid carcinoma, an undifferentiated carcinoma and a choriocarcinoma. There are several reports in the literature on endometrial cancer with choriocarcinoma differentiation, with two distinct components in the primary tumor, and the prognosis of this tumor type is reported to be poor (9). However, only a single case of a histologically distinct coexistence of a mixed adenocarcinoma and a choriocarcinoma in the uterine corpus has been reported to date (10).

Collision tumors are an uncommon phenomenon characterized by the coexistence of two completely distinct and independent tumors at the same site. The two morphologically separate tumors are sharply demarcated from each other. This...
entity is distinct from neoplasms demonstrating heterologous or mixed elements (11). Collision tumors have been reported in various organs, such as the ovary and uterus, as well as in the esophagus, stomach, colon, lung, skin, thyroid gland and breast (12,13).

In patients with collision tumors of the uterine corpus, the median age is 64.9 years (range, 47-85 years); the histological diagnoses in previously reported collision tumors of the uterine corpus are summarized in Table I (10,13-20). Several reports determined that collision tumors of the uterine corpus were mainly composed of two distinct tumors, an endometrial carcinoma (endometrioid or serous adenocarcinoma) and a mesenchymal tumor (leiomyosarcoma or endometrial stromal sarcoma). However, in a recent report, three distinct endometrial cancers were found in the uterine corpus, a malignant mixed Müllerian tumor, a serous adenocarcinoma and an endometrioid adenocarcinoma (20). In the present case report, we identified three histologically distinct lesions in the uterine corpus, including an endometrioid carcinoma, an undifferentiated carcinoma and a choriocarcinoma.

Choriocarcinomas of the uterine corpus are rare, particularly after menopause (21). Choriocarcinomas of gestational and non-gestational origin have a distinct prognosis, but cannot be distinguished by routine histological examination (22). Molecular genetic analysis may reliably identify the genetic origin of a pure ovarian choriocarcinoma (23-25); however, as this is an unestablished and costly technique with limited availability, it was not used in this case. However, our patient was in the high-risk group of endometrial cancer due to the lymph node metastasis and the histological type, i.e., undifferentiated carcinoma (26). Thus, the patient received six cycles of TC as adjuvant chemotherapy for

<table>
<thead>
<tr>
<th>Histological diagnosis</th>
<th>No.</th>
<th>(Refs.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Two distinct tumors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endometrioid carcinoma/serous carcinoma or endometrial stromal</td>
<td>7</td>
<td>(13-17)</td>
</tr>
<tr>
<td>sarcoma/leiomyosarcoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endometrioid carcinoma/carcinosarcoma</td>
<td>1</td>
<td>(18)</td>
</tr>
<tr>
<td>Serous carcinoma/small cell carcinoma</td>
<td>1</td>
<td>(19)</td>
</tr>
<tr>
<td>Mixed cell carcinoma/choriocarcinoma</td>
<td>1</td>
<td>(10)</td>
</tr>
<tr>
<td>Three distinct tumors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serous carcinoma/endometrioid carcinoma/carcinosarcoma</td>
<td>1</td>
<td>(20)</td>
</tr>
<tr>
<td>Undifferentiated carcinoma/endometrioid carcinoma/choriocarcinoma</td>
<td>1</td>
<td>Present case</td>
</tr>
<tr>
<td>Total</td>
<td>12</td>
<td></td>
</tr>
</tbody>
</table>

Figure 2. (A) Surgical specimen displaying three distinct lesions in the uterine corpus. Histopathological examination of the hysterectomy specimen revealed: (B) An undifferentiated carcinoma invading half the thickness of the myometrium in the lower segment; (C) an endometrioid adenocarcinoma with squamous differentiation, grade 2, confined to the endometrium in the middle segment; and (D) a choriocarcinoma with lymphovascular space invasion in the fundus. Hematoxylin and eosin staining; magnification, x200.
high-risk endometrial cancer and an additional five cycles of chemotherapy with MTX, as the β-hCG level after six cycles of TC remained above the normal range.

Collision tumors of the uterine corpus are rare, with only 10 cases of two distinct tumors and 1 case of three distinct tumors reported thus far. Moreover, there was only 1 case of a collision tumor composed of a choriocarcinoma with a histologically distinct endometrial carcinoma. To the best of our knowledge, this is the first report of a collision tumor composed of three histologically distinct neoplasms, including a choriocarcinoma, an endometrioid adenocarcinoma and an undifferentiated carcinoma. The diagnosis of a collision tumor prior to surgery is difficult if the neoplasms are located in close proximity, or one tumor predominates compared with the others, as in the present case. Careful pathological examination is crucial for accurately diagnosing the neoplasms constituting the collision tumor in order to prescribe the necessary treatment for a favorable prognosis.

References